ArticleCancer cell international2025
Tetrahydropalmatine has analgesic role in mouse model of bone cancer pain by inactivating the TNF-α/uPA/PAR2/TRPV1 pathway in dorsal root ganglia.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTreatment of bone cancer pain (BCP) remains a challenge. The current paper was to research the analgesic effect of Tetrahydropalmatine (THP) on BCP and the related mechanisms.
methodsMouse model of BCP was constructed by injecting E0771 breast cancer cells into the tibia. Behavioral test was performed to research the effect of THP on pain nociception of BCP mice. Tibia and dorsal root ganglia (DRG) damage was evaluated by HE and Nissl staining. The construction of BCP cell models was conducted by co-culture DRG neurons with E0771 breast cancer cells. The effect of THP on the viability and apoptosis of BCP cell models was monitored by CCK-8 and Tunel assays. TNF-α/uPA/PAR2/TRPV1 pathway activity in DRG was detected by qRT-PCR and Western blot. Pomalidomide (PMA), exogenous TNF-α protein and Capsaicin were utilized to treat BCP mouse model and cell models to explore whether THP exerted analgesic effect via inactivating the TNF-α/uPA/PAR2/TRPV1 pathway.
resultsTHP attenuated pain nociception, relieved tibia destruction, and mitigated inflammation, neuronal death and neuronal excitotoxicity in DRG of BCP mice. It enhanced the viability, but suppressed the apoptosis of BCP cell models. The activated TNF-α/uPA/PAR2/TRPV1 pathway in BCP mouse model and cell models was abrogated by THP treatment. PMA and THP had additive effect, which combination attenuated pain nociception, tibia and DRG damage of BCP mice, and apoptosis of BCP cell models. The pain relief and the TNF-α/uPA/PAR2/TRPV1 pathway inactivation induced by THP in BCP mice was abolished by exogenous TNF-α protein or Capsaicin.
conclusionTHP exerted the analgesic role in BCP might be through inactivating the TNF-α/uPA/PAR2/TRPV1 pathway in DRG. It may be an effective drug for relieving BCP in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.